Complement C5 drugs for Paroxysmal Nocturnal Hemoglobinuria

3 tracked Complement C5 drugs in the Paroxysmal Nocturnal Hemoglobinuria race. The class explanation lives on the Complement C5 page; the full indication pipeline across every mechanism is on the Paroxysmal Nocturnal Hemoglobinuria page.

2 approved / phase 41 Phase 3

Head-to-head evidence: Eculizumab vs Pozelimab · Eculizumab vs Ravulizumab

The roster

← all Complement C5 drugs